In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL

Publication
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

Contamination of the peripheral blood stem-cell (PBSC) graft with lymphoma and residual disease remaining in the patient after high-dose therapy are two potential causes of relapse after autologous transplantation. Using a tumor-specific monoclonal antibody may be one way to purge the stem-cell graft in vivo and increase the efficacy of the preparative regimen. Rituximab (Rituxan) is an IgG1 kappa chimeric mouse/human antibody containing murine light- and heavy-chain variable regions and human gamma 1 heavy-chain and light-chain constant regions. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B-cells.

Contamination of the peripheral blood stem-cell (PBSC) graft with lymphoma and residual disease remaining in the patient after high-dose therapy are two potential causes of relapse after autologous transplantation. Using a tumor-specific monoclonal antibody may be one way to purge the stem-cell graft in vivo and increase the efficacy of the preparative regimen. Rituximab (Rituxan) is an IgG1 kappa chimeric mouse/human antibody containing murine light- and heavy-chain variable regions and human gamma 1 heavy-chain and light-chain constant regions. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B-cells.

We are conducting a trial of rituximab as an in vivo purging agent and as posttransplant adjuvant immunotherapy. Patients withNHL receive 375 mg/m² of rituximab on day 1 of mobilization, followed by 2.5 g/m² of cyclophosphamide (Cytoxan, Neosar) on day 4, and 10 µg/kg of granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) starting on day 5. Stem cells are collected using a high-volume apheresis procedure, with a goal of 5 × 106 CD34/kg. The preparative regimen consists of either cyclophosphamide and total-body irradiation or busulfan (Myleran) and cyclophosphamide. Granulocyte colony-stimulating factor is used posttransplant. One dose of rituximab is given posttransplant 7 days after platelets reach 20,000/mm³.

A total of 19 patients (11 males, 8 females), median age 50 years (range, 32-65 years), have started therapy. Diagnoses include 6 follicular center cell lymphomas, 6 mantle cell lymphomas, 4 small lymphocytic/chronic lymphocytic leukemias, 2 cases of Richter’s transformation, and 1 Waldenström’s macroglobulinemia.

Of the 19 patients, 18 patients were successfully mobilized, with a threshold of 2.0 × 106 CD34/kg (median, 1.36 × 107 CD34/kg; range 2.51 × 106-5.95 × 107 CD34/kg). No CD20+ cells were detectable by flow cytometry in any of the grafts. Of 13 patients who have reached ³ day 30, the median day to reach ³ 1,000 ANC was day 10 (range, days 7-15) and the median day to achieve unsupported platelets ³ 20,000/mm³ was day 9 (range, days 3-14). Toxicities include one patient who developed pancytopenia starting at approximately day 30, with subsequent slow recovery, and idiopathic thrombocytopenic purpura in one patient that rapidly responded to steroids.

CONCLUSION: We conclude that this is a well-tolerated regimen that successfully depletes stem-cell grafts of CD20+ cells, provides rapid engraftment, and is associated with little added toxicity. Accrual and follow-up continue.

 Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content